Cohance Lifesciences announces $10 M investment in cGMP Bioconjugation Suite in US
Summary
Cohance Lifesciences announced a $10 million investment to expand cGMP bioconjugation capabilities at its U.S. subsidiary NJ Bio. The company will build a new cGMP-compliant suite in Princeton, New Jersey to support antibody-drug conjugate development and clinical supply. NJ Bio is already running work for an existing customer and expects additional customer programs to move into the expanded facility. The new capacity should be operational by the end of Q4FY26 and will support future ADC manufacturing demand.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected